Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05949255
NA

Probiotics and Insulin Resistance in Obese Asthmatics

Sponsor: University of Alabama at Birmingham

View on ClinicalTrials.gov

Summary

In this pilot study investigators will test the hypothesis that administration of oral probiotics modulates microbiome/metabolome, lowers leptin and insulin resistance and improves clinical parameters of asthma in obese insulin resistant asthmatics. Preliminary studies with oral probiotic administration in obese asthmatics showed increased abundance of probiotics-derived Bifidobacterium species and Bifidobacterium-derived metabolite in the airways of asthmatics. Additionally, neutrophils and IL-17 producing Th17 cells were significantly reduced following probiotics administration. Based on these preliminary studies, the investigators propose to test the following aims: Specific Aim 1: Determine if probiotic administration modulates airway microbiome/metabolome in obese insulin resistant asthmatics Specific Aim 2: Determine if modulation of leptin levels and insulin sensitivity by probiotics administration correlates with airway metabolome alterations and weight loss in obese insulin resistant asthmatics Specific Aim 3: Determine if microbiome/metabolome changes in probiotics group correlates with changes in asthma biomarkers and improved clinical outcomes compared to placebo in obese insulin resistant asthmatics.

Key Details

Gender

All

Age Range

18 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

7

Start Date

2024-04-01

Completion Date

2026-06-30

Last Updated

2026-01-16

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Probiotic

10 subject will receive a probiotic daily for 12 weeks.

DIETARY_SUPPLEMENT

Placebo

10 subjects will receive a placebo daily for 12 weeks.

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States